AR089425A1 - Anticuerpo ctgf (factor de crecimiento de tejido conectivo) antihumano - Google Patents
Anticuerpo ctgf (factor de crecimiento de tejido conectivo) antihumanoInfo
- Publication number
- AR089425A1 AR089425A1 ARP120104933A ARP120104933A AR089425A1 AR 089425 A1 AR089425 A1 AR 089425A1 AR P120104933 A ARP120104933 A AR P120104933A AR P120104933 A ARP120104933 A AR P120104933A AR 089425 A1 AR089425 A1 AR 089425A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- human ctgf
- growth factor
- antihuman
- connective tissue
- Prior art date
Links
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 title abstract 2
- 239000003102 growth factor Substances 0.000 title abstract 2
- 102100031168 CCN family member 2 Human genes 0.000 title 1
- 210000002808 connective tissue Anatomy 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 102000047612 human CCN2 Human genes 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000008467 tissue growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011281811 | 2011-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089425A1 true AR089425A1 (es) | 2014-08-20 |
Family
ID=48668601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104933A AR089425A1 (es) | 2011-12-22 | 2012-12-21 | Anticuerpo ctgf (factor de crecimiento de tejido conectivo) antihumano |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9587015B2 (enExample) |
| EP (1) | EP2796550B1 (enExample) |
| JP (1) | JP6040943B2 (enExample) |
| KR (1) | KR20140107507A (enExample) |
| CN (1) | CN104011206B (enExample) |
| AR (1) | AR089425A1 (enExample) |
| BR (1) | BR112014015405A2 (enExample) |
| CA (1) | CA2859627A1 (enExample) |
| EA (1) | EA029290B1 (enExample) |
| ES (1) | ES2665851T3 (enExample) |
| IN (1) | IN2014CN04615A (enExample) |
| MX (1) | MX345019B (enExample) |
| PL (1) | PL2796550T3 (enExample) |
| PT (1) | PT2796550T (enExample) |
| TW (1) | TW201333034A (enExample) |
| WO (1) | WO2013094723A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824777A (zh) * | 2019-03-15 | 2019-05-31 | 辽宁何氏医学院 | 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| MY208454A (en) * | 2019-06-04 | 2025-05-09 | Shanghai hengrui pharmaceutical co ltd | Anti-connective tissue growth factor antibody and application thereof |
| AU2021390125A1 (en) * | 2020-12-03 | 2023-06-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-connective tissue growth factor antibody |
| US20250163158A1 (en) | 2022-06-07 | 2025-05-22 | Astellas Pharma Inc. | Pharmaceutical composition containing anti-integrin alpha11 antibody for treatment or prevention of aging-related diseases |
| WO2024095964A1 (ja) | 2022-10-31 | 2024-05-10 | アステラス製薬株式会社 | Ｔｏｌｌ様受容体７／８デュアルアゴニスト化合物を含む抗体薬物複合体 |
| TW202502816A (zh) * | 2023-03-10 | 2025-01-16 | 大陸商上海濟煜醫藥科技有限公司 | 一種靶向ｃｔｇｆ的抗體或其抗原結合片段及其應用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8808645U1 (de) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen | Anzeigeeinrichtung für Feuerlöscher |
| KR100337069B1 (ko) | 1993-03-11 | 2002-10-11 | 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 | 항-hiv모노클로날항체 |
| WO1999033878A1 (en) * | 1997-12-25 | 1999-07-08 | Japan Tobacco Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| JP4537507B2 (ja) | 1997-12-25 | 2010-09-01 | アムジェン インコーポレイテッド | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
| US6492129B1 (en) * | 1998-12-14 | 2002-12-10 | University Of Miami | Fragments of connective tissue growth factor that induce extracellular matrix synthesis, collagen synthesis and/or myofibroblast differentiation |
| US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
-
2012
- 2012-12-21 EP EP12860742.1A patent/EP2796550B1/en active Active
- 2012-12-21 CA CA2859627A patent/CA2859627A1/en not_active Abandoned
- 2012-12-21 KR KR1020147020039A patent/KR20140107507A/ko not_active Abandoned
- 2012-12-21 PL PL12860742T patent/PL2796550T3/pl unknown
- 2012-12-21 IN IN4615CHN2014 patent/IN2014CN04615A/en unknown
- 2012-12-21 US US14/367,081 patent/US9587015B2/en not_active Expired - Fee Related
- 2012-12-21 MX MX2014007681A patent/MX345019B/es active IP Right Grant
- 2012-12-21 BR BR112014015405A patent/BR112014015405A2/pt unknown
- 2012-12-21 AR ARP120104933A patent/AR089425A1/es unknown
- 2012-12-21 PT PT128607421T patent/PT2796550T/pt unknown
- 2012-12-21 EA EA201491240A patent/EA029290B1/ru not_active IP Right Cessation
- 2012-12-21 JP JP2013550349A patent/JP6040943B2/ja not_active Expired - Fee Related
- 2012-12-21 TW TW101148989A patent/TW201333034A/zh unknown
- 2012-12-21 ES ES12860742.1T patent/ES2665851T3/es active Active
- 2012-12-21 CN CN201280063995.5A patent/CN104011206B/zh not_active Expired - Fee Related
- 2012-12-21 WO PCT/JP2012/083206 patent/WO2013094723A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2665851T3 (es) | 2018-04-27 |
| MX345019B (es) | 2017-01-11 |
| EP2796550A4 (en) | 2015-08-19 |
| EA201491240A1 (ru) | 2014-11-28 |
| EP2796550B1 (en) | 2018-02-28 |
| PT2796550T (pt) | 2018-04-18 |
| US20140343258A1 (en) | 2014-11-20 |
| CN104011206A (zh) | 2014-08-27 |
| CA2859627A1 (en) | 2013-06-27 |
| WO2013094723A1 (ja) | 2013-06-27 |
| EP2796550A1 (en) | 2014-10-29 |
| US9587015B2 (en) | 2017-03-07 |
| CN104011206B (zh) | 2017-03-08 |
| TW201333034A (zh) | 2013-08-16 |
| KR20140107507A (ko) | 2014-09-04 |
| EA029290B1 (ru) | 2018-03-30 |
| IN2014CN04615A (enExample) | 2015-09-18 |
| JP6040943B2 (ja) | 2016-12-07 |
| JPWO2013094723A1 (ja) | 2015-04-27 |
| PL2796550T3 (pl) | 2018-08-31 |
| BR112014015405A2 (pt) | 2017-06-13 |
| MX2014007681A (es) | 2014-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089425A1 (es) | Anticuerpo ctgf (factor de crecimiento de tejido conectivo) antihumano | |
| AR117658A2 (es) | Anticuerpos anti-fap y métodos de uso | |
| EA201270571A1 (ru) | Человеческие il-23-антигенсвязывающие белки | |
| MY169358A (en) | Bispecific t cell activating antigen binding molecules | |
| AR098950A1 (es) | Anticuerpo contra bdca-2 humano | |
| MX2015008920A (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t. | |
| EA201491700A1 (ru) | Человеческие антитела к cd27, методы и применение | |
| EA201490433A1 (ru) | Новое антитело против ngf человека | |
| AR106201A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| EA201170204A1 (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| PE20121702A1 (es) | Proteinas de enlace cd127 | |
| AR088514A1 (es) | Inmunoligantes biespecificos dirigidos contra tnf | |
| MY166794A (en) | Antibody and antibody-containing composition | |
| EA201391312A1 (ru) | Антитело к человеческому тканевому фактору и его применение | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
| AR082149A1 (es) | Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso | |
| EA201492163A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ | |
| EA201491235A1 (ru) | Варианты полипептидов fc-pol с улучшенным связыванием неонатального рецептора fc | |
| TR201905101T4 (tr) | Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. | |
| SI2970447T1 (en) | PROTITELES AGAINST PAN-ELR + CXC KEMOCIN | |
| DK201300530A (en) | Vaccine relating to Pancreas disease in fish | |
| EA201391453A1 (ru) | Новое антитело против рецептора il-23 человека | |
| WO2012122334A3 (en) | Procollagen carboxy-terminal propeptides as a target and treatment for angiogenesis related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |